Galectin Therapeutics (NASDAQ:GALT – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.01, FiscalAI reports.
Galectin Therapeutics Price Performance
GALT stock opened at $3.05 on Monday. The company has a market capitalization of $200.87 million, a P/E ratio of -7.09 and a beta of 0.53. Galectin Therapeutics has a 12 month low of $2.03 and a 12 month high of $7.13. The firm’s fifty day simple moving average is $3.65 and its 200-day simple moving average is $3.22.
Analyst Ratings Changes
Several analysts have weighed in on GALT shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Galectin Therapeutics in a research report on Monday, September 14th. Zacks Research raised shares of Galectin Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $11.00.
Read Our Latest Analysis on GALT
Galectin Therapeutics Company Profile
Galectin Therapeutics is a clinical-stage biotechnology company developing treatments that target galectin proteins, particularly galectin-3. The company’s research focuses on diseases involving fibrosis and inflammation, as well as potential applications in cancer. Its lead drug candidate, belapectin (GR-MD-02), is an investigational galectin-3 inhibitor. Galectin Therapeutics has studied belapectin for liver disease, including nonalcoholic steatohepatitis (NASH) with cirrhosis and complications related to portal hypertension, and has also explored its use in cancer treatment.
Featured Stories
- Five stocks we like better than Galectin Therapeutics
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
